Oligomerix, Inc
Advertisement
Oligomerix, Inc. is a clinical-stage biotechnology company based in West Harrison, NY, that focuses on developing oral small molecule therapeutics aimed at combating protein aggregation in neurodegenerative diseases, including Alzheimer's disease and rare tauopathies like progressive supranuclear palsy. Their lead candidate, OLX07010, acts as a small molecule inhibitor of tau self-association, targeting the initial stages of the tau aggregation cascade.
The company is committed to pioneering disease-modifying treatments, with a pipeline that includes both OLX07010 and a second generation of compounds designed to address these progressive neurodegenerative conditions. Oligomerix is at the forefront of research in this field, recently publishing significant preclinical data on their novel therapeutic approaches.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.
Advertisement

